Prospective Study of Lymphoproliferative Diseases
Prospective Study of Lymphoproliferative Diseases
This study will help researchers learn more about non-Hodgkin's lymphoma and Hodgkin's
 lymphoma and how it is treated in Kenya. Researchers want to see if having certain viruses
 like Epstein Barr Virus (EBV), Human Immunodeficiency Virus (HIV), and Kaposi's Sarcoma
 Herpes Virus (KSHV) affects lymphoma. Patients in Kenya who agree to be in this study will
 let the resesarchers look at their medical record, follow their normal cancer care, and have
 blood drawn to look at different proteins and viruses. Researchers would also like to look at
 part of the original tumor that was taken out of each patient. Some of these samples will be
 stored at Kenyatta National Hospital and research will be done on them later. This study does
 not involve any change in treatment, but only allows the study team to follow how a patient
 in Kenya with lymphoma is treated.
Comprehensive prospective cohort study of lymphoproliferative diseases in Nairobi, Kenya.
Inclusion Criteria:

 -  All subjects regardless of age, sex or HIV serostatus must have biopsy-proven
 non-Hodgkin's (NHL), including primary effusion lymphoma, Hodgkin's lymphoma (HD) or
 other lymphoproliferative disorder (e.g., Castleman's disease) with measurable or
 evaluable stage I through IV disease.

 [Note: Lymphomas will be categorized on the basis of current WHO classification scheme, but
 it is recognized that initial pathological categorization at time of study enrollment will
 more than likely be classified or graded as low-, intermediate-, or high-grade lymphoma by
 Working Formulation criteria. This is the current standard of practice in Kenya.]

 -  All subjects must receive some form of systemic chemotherapy. Subjects not receiving
 chemotherapy of any kind are not eligible. Subjects must not have had any prior
 chemotherapy for lymphoma.

 -  Subjects may have received prior radiotherapy for localized stage I or stage II
 disease that is clearly documented to have progressed beyond initial radiotherapy
 ports.

 -  All subjects must give written informed consent to participate on study. In Kenya, a
 child is considered < 18 years of age and an adult ≥ 18 years of age. All children
 will have their parental or legal guardian provide consent.. Children between the ages
 of 7 and < 18 years old should be given the opportunity to provide their assent. For
 children between the ages of 7 and 11 years old this should be done using the parental
 consent form assent statement. For children > 11 years old assent should be documented
 using the IRB approved assent form.

 Exclusion Criteria:

 -  Subjects who do not fulfill the criteria as listed in Sections 3.1.1 through 3.1.4 are
 ineligible.

 -  Subjects who received prior chemotherapy (i.e., first-line treatment) or are not
 receiving any chemotherapy for their non-Hodgkin's (NHL) or Hodgkin's lymphoma (HD)
 are ineligible.